Peak Bggrflipped into Biotech InvestingEmphysema Pulmatrix up 49% premarket on J&J deal Seeking Alpha - Douglas W. House Thinly traded nano cap Pulmatrix (NASDAQ:PULM) is up 49% premarket on robust volume in reaction to its license and development deal with Johnson & …
Opioids AG Ferguson sues Johnson & Johnson for state opioid epidemic komonews.com - KOMO News Staff SEATTLE -- Washington Attorney General Bob Ferguson filed a lawsuit Thursday against Johnson & Johnson, asserting that J & J, along with several of …
SeattlePIflipped into LocalOpioids AG Ferguson sues Johnson & Johnson -- 'unique role' in opioid epidemic seattlepi.com - Joel Connelly The state of Washington is suing Johnson & Johnson, charging the pharmaceutical giant with producing opioid painkillers, supplying addictive …
The Daily Beastflipped into Cheat SheetOpioids Washington Attorney General Sues Johnson & Johnson Over Opioid Crisis The Daily Beast - Julia Arciga Washington's attorney general filed a lawsuit Thursday against Johnson & Johnson, claiming the company is one of the largest suppliers of raw …
Patchflipped into Seattle, WA PatchOpioids Washington State AG Sues Pharma Giant Over Opioid Crisis Patch - Nick Garber SEATTLE, WA — The state of Washington filed a lawsuit Thursday against pharmaceutical giant Johnson & Johnson, accusing the company of negligence by …
Seeking AlphaInvesting Washington state sues J&J over role in opioid epidemic Seeking Alpha - Douglas W. House Washington is the latest state to file litigation against Johnson & Johnson (JNJ -0.4%) over its role in the opioid crisis there. A trial in New York …
Seeking AlphaMyeloma Johnson & Johnson declares $0.95 dividend Seeking Alpha - Mamta Mayani Johnson & Johnson (NYSE:JNJ) declares $0.95/share quarterly dividend, in line with previous. Payable March 10; for shareholders of record Feb. 25; …
Alan Nishiharaflipped into Alan Nishihara's Flipboard MagazineInvesting If You Invested $10,000 in Johnson & Johnson's IPO, This Is How Much Money You'd Have Now The Motley Fool - Taylor Carmichael The pharma giant began as the first seller of First Aid Kits, going public in 1944. Here's how early investors fared in its meteoric rise. Taylor …
scepperflipped into Money HoneyInvesting Does Johnson & Johnson’s Dividend Make It A Buy? The Motley Fool - David Jagielski Its growing dividend could make it an ideal stock to hold for long-term investors. Finding a good dividend stock can be a challenge, as investors need …
Barron'sflipped into Barron'sBusiness Investors Have Been Optimistic About Opioid Litigation. It’ll Still Be an Issue in 2020. Barron's - Josh Nathan-Kazis At the end of 2019, the optimism among investors that the opioid litigation was nearing some kind of a neat conclusion seemed increasingly …
The Motley FoolInvesting Better Buy: Pfizer vs. Johnson & Johnson The Motley Fool - Keith Speights Which stock wins in a matchup between these two healthcare giants? Keith began writing for the Fool in 2012 and focuses primarily on healthcare …
Barron'sflipped into Barron'sInvesting Johnson & Johnson Spent 2019 Dogged by Lawsuits Barron's - Josh Nathan-Kazis Whether you thought Johnson & Johnson shares were overpriced or underpriced in 2019 hinged largely on how your answer to this question: How big of a …
The Motley FoolInvesting Can Johnson & Johnson Break Out In 2020? The Motley Fool - Ryan Patrick The healthcare giant has been meandering and volatile for two years. What can drive the stock higher next year? Johnson & Johnson (NYSE:JNJ) enjoyed …
TheStreetflipped into InvestingInvesting Johnson & Johnson's Tremfya Plaque-Psoriasis Treatment Is Cleared by China for Import TheStreet - Rob Lenihan Johnson & Johnson is positioning Tremfya as an alternative to a top seller, Novartis's Cosentyx, according to a media report. China has approved …
Reuters IndiaChina China regulator approves imports of J&J's Tremfya Reuters IndiaFILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, U.S., September
Peak Bggrflipped into Biotech InvestingChina Johnson & Johnson's Tremfya gets China approval Seeking Alpha - Brandy Betz China's National Medical Products Administration approves imports of Johnson & Johnson's (NYSE:JNJ) Tremfya. Tremfya will be used to treat moderate to …
Startups (India) Icertis | YourStory yourstory.com Third homegrown software products company to enter the elite unicorn club Icertis is a software company that provides contract management software to …
Forbesflipped into FinanceFinance How Does Johnson & Johnson’s Revenue And Other Key Metrics Compare With That of Roche? Forbes - Trefis TeamJohnson & Johnson and Roche (OTCMKTS: RHHBY) are both primarily engaged in the pharmaceutical business. Johnson & Johnson generated $82 billion in sales in 2018, while Roche garnered $61 billion. For companies,
News18.comflipped into News18 Latest NewsGST Johnson & Johnson India Fined Rs 230.4 Crore For Profiteering From Cut in GST Rates news18.com - News18.com In an order issued on Monday by National Anti-Profiteering Authority, Johnson and Johnson was asked to pay back the amount within a period of three …
Oklahoma Politics Oklahoma Supreme Court retains jurisdiction of appeals filed in... oklahoman.com - Randy Ellis Oklahoma Supreme Court retains jurisdiction of appeals filed in state case against opioid manufacturer The Oklahoma Supreme Court will retain …
The Economic Timesflipped into ET's Top StoriesGST GST profiteering: Rs 230-crore penalty on Johnson & Johnson indiatimes.com New Delhi: The National Anti-Profiteering Authority has slapped a Rs 230 crore penalty against baby products maker Johnson& Johnson for profiteering …
FOX Businessflipped into MarketsAsbestos Jury backs Johnson & Johnson in talc cancer case FOX Business - Associated PressST. LOUIS (AP) — A St. Louis jury has ruled in favor of Johnson & Johnson in the latest of several lawsuits alleging that the company’s baby powder caused ovarian cancer. The jury ruled 9-3 late Friday,
Bui Danflipped into DAN COLLECTIONDocMedical Technology Johnson & Johnson buys out Verily stake in Verb Surgical therobotreport.com - Eugene Demaitre
The Wall Street Journal.Cancer Drugmakers Turn to Data Mining to Avoid Expensive, Lengthy Drug Trials The Wall Street Journal. - Peter LoftusPfizer, Johnson & Johnson and Amgen try to win drug approvals by analyzing vast data sets of electronic medical records Drugmakers are trying to win drug approvals by parsing vast data sets of electronic
Barron'sflipped into Barron'sBusiness Johnson & Johnson Stock Gets More Good News, but a Big Test Is On the Way Barron's - Josh Nathan-Kazis A string of victories in talc litigation seems like a good sign for Johnson & Johnson stock, but the real test is coming soon. On Friday, a jury in a …
Forbesflipped into FinanceFinance Johnson & Johnson’s COGS On the Rise? Forbes - Trefis TeamJohnson & Johnson’s (NYSE: JNJ) cost of goods sold has been on a rise. It accounted for 41% of its total expenses in 2018, compared to 39% in 2016. In fact, Johnson & Johnson’s COGS, when looked at as
Business Insiderflipped into Top StoriesRobotics Johnson & Johnson is wading deeper into surgical robotics - Business Insider Business Insider - Zachary HendricksonThe healthcare multinational announced an agreement to acquire the remaining stake in the surgical innovation JV born out of a strategic collaboration between Johnson & Johnson's (J&J's) Ethicon division
Finance (India) Johnson Johnson gets clearance in baby powder-cancer trial in US businesstoday.in - HomePodcastBulletin Johnson & Johnson gets clearance in baby powder-cancer trial in US The baby powder of Johnson & Johnson is not responsible for a Missouri woman's …
Firstpostflipped into FirstPostAsbestos Johnson Johnson cleared in baby powder-cancer litigation case in US; talc does not contain asbestos, says jury - Firstpost Firstpost - Press Trust of India Delaware, USA: The baby powder of Johnson & Johnson is not responsible for a Missouri woman's cancer, a jury in the US has decided in the company's …
Ebola Johnson & Johnson to Deliver up to Half A Million Doses of Their Ebola Vaccine to the Democratic Republic of the Congo globalcitizen.org - By Jackie Marchildon The current Ebola outbreak has infected more than 3,000 people. Janssen, part of the Pharmaceutical Companies of Johnson & Johnson will be providing …
